CEO of Fluofarma, Jean-Baptiste Pin has over 10 years experience in the
pharmaceutical and biotechnology industries in the areas of general management
and business development. Before joining Fluofarma, he was a Senior Consultant
at Ernst & Young specialized in Biotechnology.
Dr François Ichas, is the scientific director of Fluofarma and brings a strong expertise in cell biology and cell-based assays design. Dr Ichas holds a PhD in Biomedical Sciences (1997) followed by several post-doctoral positions as well as a Group Leader Fellowship at the European Institute of Chemistry and Biology. He coauthored over 40 peer reviewed scientific publications and patents. Dr Ichas is co-founder of Fluofarma, and as INSERM Research Director, is in charge of promoting and organizing new translational & interdisciplinary research axes at the INSERM Apoptosis and Cancer laboratory U916 VINCO.
Bruno has been in the biotech business for 15 years thus brings to Fluofarma extensive experience in corporate and business development. After spending some years in technology transfer, he has held a position as a Research Associate and Business Analyst in a consulting firm of Chicago, USA. Thereafter, he held several Business Development and General Management positions at biotech and medtech companies (Cellectis, Mauna Kea Technologies, Biospace Lab).
Project manager at Fluofarma, Loïc plays a key role in managing relationship between our scientist team and our clients. He is also responsible for the supervision of Fluofarma European projects.
Marketing manager at Fluofarma, Julie is responsible for corporate communication, strategic watch and marketing intelligence. Before joining the company, she worked as Licensing Manager for Avenium Consulting, the technology transfer office of the French public R&D establishment CEA.
Roche adopts Fluofarma’s platform
October 19, 2009 – Fluofarma announced today that it entered into
a multi-year agreement with Roche.
Read
More